Siemens’ PETNET Solutions, a wholly owned subsidiary of Siemens Healthcare, has signed an agreement with Navidea Biopharmaceuticals that grants Siemens’ PETNET Solutions the right to manufacture Navidea’s Fluorine-18 labeled NAV4694.
The product is currently being assessed in Phase II and Phase III clinical trials as a beta-amyloid PET imaging agent. Beta-amyloid plaque is one of the necessary pathological features of Alzheimer’s disease/ PET amyloid scans can help visualize beta-amyloid plaque in the living brain. Under the terms of its agreement with Navidea, Siemens’ PETNET Solutions will initially manufacture NAV4694 at select U.S. radiopharmacies, with the possibility of expanding into additional PETNET Solutions locations next year.
